Alzheimer’s and Parkinson’s Diseases: Progress and New Perspectives

8th International Conference AD/PD
Salzburg, Austria, March 14–18, 2007

PROCEEDINGS

Guest Editors

Israel Hanin, Tucson, Ariz.
Manfred Windisch, Graz
Werner Poewe, Innsbruck
Abraham Fisher, Ness Ziona

39 figures, 4 in color, and 11 tables, 2008
Contents

113 Preface
Hanin, I. (Tucson, Ariz.); Windisch, M. (Graz); Poewe, W. (Innsbruck); Fisher, A. (Ness Ziona)

Keynote Address
114 Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an Eyewitness
Hornykiewicz, O. (Vienna)

AD/PD – General Considerations
118 Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia
Jellinger, K.A. (Vienna)

122 Etiology and Pathophysiology of Frontotemporal Dementia, Parkinson Disease and Alzheimer Disease: Lessons from Genetic Studies
Wider, C.; Wszolek, Z.K. (Jacksonville, Fla.)

126 Pathophysiology of Neuronal Energy Crisis in Alzheimer's Disease
de la Torre, J.C. (Cleveland, Ohio)

129 Early Detection of Parkinson's and Alzheimer's Disease
Berg, D. (Tübingen)

137 Early Detection of Parkinson’s Disease: Unmet Needs
Gerlach, M. (Würzburg); Hendrich, A. (Bietigheim-Bissingen); Hueber, R. (Bergisch Gladbach); Jost, W. (Wiesbaden); Winkler, J. (Regensburg); Woitalla, D. (Bochum); Riederer, P. (Würzburg)

Beta-Amyloid

140 Intraneuronal β-Amyloid Is a Major Risk Factor – Novel Evidence from the APP/PS1KI Mouse Model
Bayer, T.A.; Breyhan, H. (Goettingen); Duan, K.; Rettig, J. (Homburg); Wirths, O. (Goettingen)

143 Physiologic Origins of Age-Related β-Amyloid Deposition
Beach, T.G. (Sun City, Ariz.)

146 Impact of Intracellular β-Amyloid in Transgenic Animals and Cell Models
Cuello, A.C.; Canneva, F. (Montreal, Que.)

149 β-Amyloid Oligomers Affect the Structure and Function of the Postsynaptic Region: Role of the Wnt Signaling Pathway
Dinamarca, M.C.; Colombres, M.; Cerpa, W. (Santiago); Bonansco, C. (Valparaiso); Inestrosa, N.C. (Santiago)

Potent β-Amyloid Modulators

157 Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice
Eckert, A. (Basel); Hauptmann, S.; Scherping, I. (Frankfurt); Rhein, V.; Müller-Spahn, F. (Basel); Götz, J. (Camperdown, N.S.W.); Müller, W.E. (Frankfurt)

Processes of β-Amyloid and Intracellular Cytoplasmic Domain Generation by Presenilin/γ-Secretase

Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid Secretion
Robert, S.J.; Lezoualc’h, F. (Châtenay-Malabry)

Preamyloid

166 Activation of the Amyloid Cascade by Intracerebroventricular Injection of the Protease Inhibitor Phosphoramidon
Nisemblat, Y.; Belinson, H.; Dolev, I.; Michaelson, D.M. (Tel-Aviv)

170 Mechanism of Glial Differentiation of Neural Progenitor Cells by Amyloid Precursor Protein
Sugaya, K. (Orlando, Fla.)

173 Preamyloid Lesions and Cerebrovascular Deposits in the Mechanism of Dementia: Lessons from Non-β-Amyloid Cerebral Amyloidosis
Rostagno, A.; Ghiso, J. (New York, N.Y.)

Genetics

176 Influence of Pharmacogenetic Factors on Alzheimer’s Disease Therapeutics
Cacabelos, R. (Bergondo)

179 Functional Genomics Dissects Pathomechanisms in Tauopathies: Mitosis Failure and Unfolded Protein Response
Götz, J.; David, D. (Camperdown, N.S.W.); Hoernndli, F. (Zurich); Ke, Y.D.; Schonrock, N.; Wiesner, A. (Camperdown, N.S.W.); Fath, T. (Westmead, N.S.W.); Bokhari, L.; Lim, Y-A.; Deters, N.; Ittner, L.M. (Camperdown, N.S.W.)

182 Investigating Convergent Actions of Genes Linked to Familial Parkinson’s Disease
Wolozin, B.; Saha, S.; Guillily, M.; Ferrere, A.; Riley, M. (Boston, Mass.)
222 Leucine-Rich Repeat Kinase 2 Colocalizes with In vivo and Postmortem Clinicoanatomical Correlations in ACAT as a Drug Target for Alzheimer’s Disease

206 Regulation of proBACE1 by Glycosaminoglycans

194 Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

197 Engineered Heparins: Novel β-Secretase Inhibitors as Potential Alzheimer’s Disease Therapeutics

190 Neuroinflammation in Plaque and Vascular β-Amyloid Disorders: Clinical and Therapeutic Implications

186 Apolipoprotein E ε 4 Allele Is Associated with Atrophy in Progressive Mild Cognitive Impairment: A Voxel-Based Morphometric Study


181 Infammation

179 Neuronal and Inflammatory Markers in Alzheimer’s Disease

178 Specificity of Inflammatory Markers in Alzheimer’s Disease

174 The Role of Brain Inflammation in Alzheimer’s Disease

173 Inflammation and Alzheimer’s Disease

171 The Expression of Inflammatory Markers in Alzheimer’s Disease

167 Neuroprotective Properties of Glycosaminoglycans: Potential Treatment for Neurodegenerative Disorders

165 Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease

163 The Long-Term Effects of Oophorectomy on Cognitive and Motor Aging Are Age Dependent

159 The Role of Alpha-Synuclein in Neurodegenerative Diseases: A Potential Target for New Treatment Strategies?

155 The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System

151 Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimer’s Disease

149 Various Markers

145 The Long-Term Effects of Oophorectomy on Cognitive and Motor Aging Are Age Dependent

142 Polymorphisms at the Paraoxonase 1 L55M and Q192R Loci Affect the Pathophysiology of Alzheimer’s Disease: Emphasis on the Cholinergic System and Beta-Amyloid Levels

138 The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System

133 Subject Index Vol. 5, No. 3–4, 2008

131 Author Index Vol. 5, No. 3–4, 2008

127 The Role of Alpha-Synuclein in Parkinson’s Disease

124 Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease

120 ACAT as a Drug Target for Alzheimer’s Disease

116 Various Markers

112 The Long-Term Effects of Oophorectomy on Cognitive and Motor Aging Are Age Dependent

110 Polymorphisms at the Paraoxonase 1 L55M and Q192R Loci Affect the Pathophysiology of Alzheimer’s Disease: Emphasis on the Cholinergic System and Beta-Amyloid Levels

106 Various Markers

102 Neuroprotective Properties of Glycosaminoglycans: Potential Treatment for Neurodegenerative Disorders

100 Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease

96 The Role of Alpha-Synuclein in Parkinson’s Disease

92 Various Markers

88 Polymorphisms at the Paraoxonase 1 L55M and Q192R Loci Affect the Pathophysiology of Alzheimer’s Disease: Emphasis on the Cholinergic System and Beta-Amyloid Levels

84 The Role of Alpha-Synuclein in Parkinson’s Disease

80 Various Markers

76 Various Markers

72 The Role of Alpha-Synuclein in Parkinson’s Disease

68 Various Markers

64 The Role of Alpha-Synuclein in Parkinson’s Disease

60 Various Markers

56 Various Markers

52 Various Markers

48 Various Markers

44 Various Markers

40 Various Markers

36 Various Markers

32 Various Markers

28 Various Markers

24 Various Markers

20 Various Markers

16 Various Markers

12 Various Markers

8 Various Markers

4 Various Markers

0 Various Markers

Downloaded on 11/1/2017 9:07:41 PM